download
print

Press Releases

press releases

Date Title
Aug 03, 2022 Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Aug 02, 2022 Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
Jul 28, 2022 Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Jul 27, 2022 Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
Jul 22, 2022 Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Jul 18, 2022 Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
Jun 13, 2022 Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Jun 09, 2022 Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Jun 02, 2022 Alnylam to Webcast Presentations at Upcoming June Investor Conferences
Jun 02, 2022 Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

Sr. Director, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276

MEDIA KIT

Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?

Contact: investors@alnylam.com